Memantina Kern Pharma

Memantine Hydrochloride, the active ingredient in Memantina Kern Pharma, is an NMDA receptor antagonist presented as an oral tablet for oral use. It is used to provide symptomatic treatment of cognitive decline in patients with Alzheimer’s disease.

GNH USA supplies Memantina Kern Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for healthcare providers across multiple regions. All shipments are handled under Good Distribution Practice to ensure product integrity during transport.

Memantina Kern Pharma (memantine) is indicated for the management of Alzheimer’s disease, targeting the glutamatergic pathway that contributes to neurodegeneration. - Alzheimer’s disease (moderate to severe): improves cognition and daily functional abilities. - Alzheimer’s disease (mild to moderate): may slow the progression of memory loss and executive dysfunction. - Alzheimer’s disease (behavioral symptoms): may reduce agitation, aggression and psychosis associated with the disease.

Memantina Kern Pharma may be associated with a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Dizziness: transient sensation of light‑headedness. - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Fatigue: feeling of tiredness. - Nausea: occasional upset stomach. - Vomiting: occasional emesis. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Seizures: rare occurrence of convulsive episodes. - Allergic reaction: rash, itching, swelling, or anaphylaxis. - Hallucinations: visual or auditory disturbances. - Severe confusion: marked disorientation or delirium. - Psychosis: emergence of delusional thoughts.

When prescribing Memantina Kern Pharma, clinicians should consider several precautionary measures to ensure safe use. - Renal impairment: adjust dose or monitor renal function in patients with reduced clearance. - Hepatic dysfunction: use with caution in moderate to severe liver disease. - Concomitant NMDA antagonists: avoid combined use due to additive CNS effects. - History of seizures: monitor closely as memantine may lower seizure threshold. - Cardiovascular disease: assess risk as dizziness may affect blood pressure. - Store at ambient temperature: keep below 25 °C, retain in original packaging and protect from moisture.

Memantine can interact with other medicines, influencing its plasma levels or enhancing central nervous system effects.

Major Interactions (Avoid): - Amantadine: combined NMDA antagonism may increase neuropsychiatric adverse events. - Ketamine: additive NMDA blockade can lead to excessive sedation or psychotomimetic effects. - High‑dose quinidine: may raise memantine concentrations, increasing toxicity risk.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may worsen cognitive impairment when used together. - Carbamazepine: enzyme induction may reduce memantine exposure. - Proton pump inhibitors: may slightly increase memantine levels, requiring observation.